Default Category
-
Tequila Patr n
Deshpande, Rohit; Castellanos Rodriguez, Carlos; Cacho-Elizondo, Silvia; Rullan, Samantha; Miguel, FernandaCase HBS-517108-EMarketingTequila Patr n was one of the most successful tequila marketers in the United States. Patr n needed to grow and in Mexico, the second largest market for tequila, the brand was perceived as American. What portfolio and branding strategy would best serve Patr n to conquer the Mexican market? Furthermore, what would expanding in Mexico imply for the company's marketing operations?Starting at €8.20
-
Paydiant
Alvarez, Jose B.; Williamson, Elizabeth C.; Weber, JamesCase HBS-511065-EMarketingTo maximize their effectiveness, color cases should be printed in color. Kevin Laracey, founder of Paydiant, needed to figure out how to launch a payment processing company with a new technology based on smart phones. Consumers had increasingly turned to electronic payment methods such as credit cards and debit cards to make purchases. Retailers, however, felt that major credit and debit card issuers had too much market power which was leading to...Starting at €8.20
-
Pfizer and AstraZeneca: Marketing an Acquisition (B)
Quelch, John A.; Weber, JamesCase HBS-515008-EMarketingThis (B) case provides a brief description of the outcome of the (A) case.Starting at €5.74
-
Tequila Patr n (Spanish version)
Deshpande, Rohit; Castellanos Rodriguez, Carlos; Cacho-Elizondo, Silvia; Rullan, Samantha; Miguel, FernandaCase HBS-518S01MarketingTequila Patr n was one of the most successful tequila marketers in the United States. Patr n needed to grow and in Mexico, the second largest market for tequila, the brand was perceived as American. What portfolio and branding strategy would best serve Patr n to conquer the Mexican market? Furthermore, what would expanding in Mexico imply for the company's marketing operations?Starting at €8.20
-
Pfizer and AstraZeneca: Marketing an Acquisition (A)
Quelch, John A.; Weber, JamesCase HBS-515007-EMarketingIn 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to the challenges of developing new drugs. Over the previous decade or more, Pfizer had pursued acquisitions as a way to acquire new drugs, increase sales, and to reduce costs by comb...Starting at €8.20